-
Illumina Inc. (ILMN $99.25)
- $99.25 Cap: $15.71B
- View ILMN Profile
- View Questions on ILMN
Detailed Quote
Questions on this company?
Become a Member
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Illumina Inc. (ILMN $99.25)
- $99.25 Cap: $15.71B
- View ILMN Profile
- View Questions on ILMN
Q: Why is ILMN your favourite in Multiomic sequencing? And is this a good price point to start a position?
-
Illumina Inc. (ILMN $99.25)
- $99.25 Cap: $15.71B
- View ILMN Profile
- View Questions on ILMN
-
Pacific Biosciences of California Inc. (PACB $1.47)
- $1.47 Cap: $444M
- View PACB Profile
- View Questions on PACB
-
CRISPR Therapeutics AG (CRSP $56.80)
- $56.80 Cap: $4.90B
- View CRSP Profile
- View Questions on CRSP
-
Bio-Techne Corp (TECH $54.14)
- $54.14 Fwd P/E: 65.23X Cap: $8.24B
- View TECH Profile
- View Questions on TECH
-
10x Genomics Inc. (TXG $12.80)
- $12.80 Cap: $1.57B
- View TXG Profile
- View Questions on TXG
Q: Can you recommend stocks or ETFs in Multiomic sequencing
-
Gilead Sciences Inc. (GILD $109.64)
- $109.64 Fwd P/E: 23.03X Cap: $136.38B
- View GILD Profile
- View Questions on GILD
-
Illumina Inc. (ILMN $99.25)
- $99.25 Cap: $15.71B
- View ILMN Profile
- View Questions on ILMN
-
Intuitive Surgical Inc. (ISRG $512.06)
- $512.06 Fwd P/E: 74.97X Cap: $183.53B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $192.45)
- $192.45 Fwd P/E: 82.24X Cap: $339.94B
- View ABBV Profile
- View Questions on ABBV
-
Eli Lilly and Company (LLY $793.01)
- $793.01 Fwd P/E: 64.52X Cap: $751.56B
- View LLY Profile
- View Questions on LLY
-
UnitedHealth Group Incorporated (DE) (UNH $304.10)
- $304.10 Fwd P/E: 12.73X Cap: $275.86B
- View UNH Profile
- View Questions on UNH
-
Novo Nordisk A/S (NVO $68.93)
- $68.93 Fwd P/E: 19.74X Cap: $363.68B
- View NVO Profile
- View Questions on NVO
-
BioMarin Pharmaceutical Inc. (BMRN $58.10)
- $58.10 Fwd P/E: 21.6X Cap: $11.44B
- View BMRN Profile
- View Questions on BMRN
Q: I am working on increasing my sector representation in Healthcare. I will shortly have filled a full position in ISRG, adding in this downturn. I have traded around UNH, and am planning to take it from a 1/2 to full position. I have 1/4 position in ILMN and do not think I should be topping it up; I perceive it to be risky. I need 2 more companies, or may need to take one or both of IRSG/UNH to more than a full position.
This provides me a surgical/instrumentation company and a service/product supplier. For diversity in the Healthcare space can you rank your preferred buys (with entry points) I'd appreciate 2 recommendations on the pharmaseuticals side and 2 on the biotech side, or as you may see that fits better.
While I am open US companies I do have a concern that the Trump administration will bring the DOGE and Executive Order train wrecks to health care. I would appreciate your views on this potential action and howe it may impact investment choice in the field.
Thanks as always,
Dave
This provides me a surgical/instrumentation company and a service/product supplier. For diversity in the Healthcare space can you rank your preferred buys (with entry points) I'd appreciate 2 recommendations on the pharmaseuticals side and 2 on the biotech side, or as you may see that fits better.
While I am open US companies I do have a concern that the Trump administration will bring the DOGE and Executive Order train wrecks to health care. I would appreciate your views on this potential action and howe it may impact investment choice in the field.
Thanks as always,
Dave
Insiders
Share Information
SEC Filings
News and Media